The FDA has granted fast track designation to MT-125 for the treatment of patients with glioblastoma. The U.S. Food and Drug ...

Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular ...

In a phase 2b trial, danicamtiv, a novel cardiac myosin activator, was well tolerated and associated with improved heart ...

MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...

Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease. It causes the left ventricle to thicken, the ...

Each year, about 14,000 people in the United States are diagnosed with glioblastoma, one of the deadliest primary brain tumors. With standard treatments of surgery, radiation, and chemotherapy ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A mutation in the myosin heavy chain 11 gene has been ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ...

The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean ...

"This process appears to be regulated by myosin-binding protein-C (cMyBP-C), which is a heart muscle protein," study author Kerry McDonald said. "Our study investigated its role in cardiac muscle ...

During the development of hypertrophy, cardiac myocytes increase organization of the sarcomere, a highly ordered contractile unit in striated muscle cells. Several hypertrophic agonists, such as ...